Sichuan Kelun-Biotech Biopharmaceutical Past Earnings Performance
Past criteria checks 0/6
Sichuan Kelun-Biotech Biopharmaceutical has been growing earnings at an average annual rate of 4.7%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 91.6% per year.
Key information
4.7%
Earnings growth rate
50.4%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | 91.6% |
Return on equity | -24.6% |
Net Margin | -33.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth
Jun 14Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results
Mar 27An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued
Jan 11Revenue & Expenses Breakdown
How Sichuan Kelun-Biotech Biopharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,540 | -522 | 199 | 1,031 |
30 Sep 23 | 1,523 | -427 | 170 | 1,012 |
30 Jun 23 | 1,505 | -333 | 140 | 993 |
31 Mar 23 | 1,155 | -440 | 117 | 919 |
31 Dec 22 | 804 | -548 | 93 | 846 |
31 Dec 21 | 32 | -823 | 91 | 728 |
Quality Earnings: 6990 is currently unprofitable.
Growing Profit Margin: 6990 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 6990's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 6990's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6990 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 6990 has a negative Return on Equity (-24.65%), as it is currently unprofitable.